FINWIRES · TerminalLIVE
FINWIRES

$URGN

7 stories mentioning URGN

Every FINWIRES story that references URGN, newest first.

Sectors

Sector Update: Healthcare Stocks Gain Late Afternoon

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding about 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In sector news, Boston Scientific (BSX) shares gained 1.9% after the company said Tuesday a trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.Tiziana Life Sciences' (TLSA) intranasal foralumab showed good long-term tolerability and fatigue improvement in an expanded access program involving 14 patients with non-active secondary progressive multiple sclerosis based on updated clinical data, the company said. Its shares rose 3%.UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with a physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.8%.MetaVia (MTVA) shares surged 64% Tuesday, a day after the company said three late-breaking abstracts highlighting its cardiometabolic assets were accepted for poster presentations at the American Diabetes Association's 2026 Scientific Sessions.

$BSX$MTVA$TLSA$URGN
Sectors

Sector Update: Health Care

Healthcare stocks rose late Tuesday afternoon, with the NYSE Healthcare Index and the State Street Healthcare Select Sector SPDR ETF (XLV) each adding 1.2%.The iShares Biotechnology ETF (IBB) increased 0.2%.In sector news, UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with the physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said in a note. UroGen shares were down 0.5%.

$URGN
Wire

UroGen Pharma Investor Event Reinforced Zusduri Commercial Thesis, Oppenheimer Says

UroGen Pharma's (URGN) investor event reinforced the commercial thesis for Zusduri in low-grade intermediate-risk non-muscle invasive bladder cancer, with the physician panel suggesting that peers may face tough competition unless they can offer overwhelmingly better efficacy, Oppenheimer said Tuesday.The physician panel said Zusduri has a competitive advantage since it is first to market, requires no biomarker testing, can be used without transurethral resection of bladder tumor or TURBT surgery, and has a finite six-dose treatment course, according to the note.One panelist argued that Zusduri offers better long-term durability than surgery, with roughly a 65% chance of no tumor recurrence at three years, something TURBT cannot offer, the brokerage said.The treatment seems operationally feasible and reimbursement concerns are easing, but Medicare Advantage plans remain a risk because clinics could still lose money despite the drug being officially covered, the brokerage added.Oppenheimer's above-consensus Zusduri revenue estimates for 2026 to 2030 of $204 million, $411 million, $595 million, $771 million, and $931 million remain unchanged.The brokerage kept an outperform rating on UroGen Pharma with a price target of $40.Price: $27.64, Change: $-0.94, Percent Change: -3.29%

$URGN
Sectors

Sector Update: Healthcare Stocks Advance Wednesday Afternoon

Healthcare stocks rose Wednesday afternoon, with the NYSE Healthcare Index adding 0.8% and the State Street Healthcare Select Sector SPDR ETF (XLV) increasing 0.5%.The iShares Biotechnology ETF (IBB) eased 0.1%.In corporate news, Personalis (PSNL) shares jumped past 7% after the company said the Molecular Diagnostic Services Program of the Centers for Medicare & Medicaid Services expanded coverage for its NeXT Personal minimal residual disease test.Assertio (ASRT) shares rose 3.4% after the company said Wednesday it agreed to be acquired by Zydus Lifesciences subsidiary Zydus Worldwide DMCC in an all-cash tender offer valued at about $166.4 million.UroGen Pharma's (URGN) Zusduri treatment demonstrated a 64.5% 36-month duration of response in a pivotal phase 3 trial in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, the company said Wednesday. Its shares rose 1.9%.

$ASRT$PSNL$URGN
Insider Trading

Urogen Pharma Insider Sold Shares Worth $300,000, According to a Recent SEC Filing

Mark Schoenberg, Chief Medical Officer, on May 08, 2026, sold 10,000 shares in Urogen Pharma (URGN) for $300,000. Following the Form 4 filing with the SEC, Schoenberg has control over a total of 134,985 ordinary shares of the company, with 134,985 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1668243/000143774926016104/xslF345X05/rdgdoc.xmlPrice: $31.50, Change: $+2.10, Percent Change: +7.14%

$URGN
Wire

Oppenheimer Adjusts Price Target on UroGen Pharma to $40 From $34, Maintains Outperform Rating

UroGen Pharma (URGN) has an average rating of buy and mean price target of $34.62, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $25.55, Change: $-0.70, Percent Change: -2.69%

$URGN
Wire

UroGen Pharma Shares Rise on Narrower Q1 Net Loss, Higher Revenue

UroGen Pharma (URGN) shares were up 9.9% in early trading on Wednesday after the company posted a narrower net loss and higher revenue for Q1.The company reported a Q1 net loss of $0.47 per diluted share, narrower than a loss of $0.92 a year earlier.Analysts polled by FactSet expected a loss of $0.48.Revenue for the quarter ended March 31 was $51 million, up from $20.3 million a year earlier.Analysts expected revenue of $44.8 million.As of March 31, the company said it had $140.3 million in cash, cash equivalents and marketable securities on hand.Price: $26.25, Change: $+2.42, Percent Change: +10.16%

$URGN